Cinctive Capital Management LP Buys New Position in United Therapeutics Corporation $UTHR

Cinctive Capital Management LP bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, Holdings Channel.com reports. The fund bought 7,507 shares of the biotechnology company’s stock, valued at approximately $3,147,000.

Several other institutional investors also recently added to or reduced their stakes in the business. Clearstead Advisors LLC lifted its holdings in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares during the last quarter. Archer Investment Corp increased its position in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 31 shares during the period. F m Investments LLC increased its position in United Therapeutics by 1.3% during the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 33 shares during the period. Finally, WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $483.16, for a total value of $4,010,228.00. Following the completion of the sale, the executive vice president directly owned 36,844 shares in the company, valued at $17,801,547.04. This trade represents a 18.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total value of $5,125,630.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $70,140.20. This represents a 98.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 307,930 shares of company stock valued at $150,132,812 over the last quarter. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $536.12 on Monday. The firm has a 50 day simple moving average of $486.67 and a 200 day simple moving average of $462.28. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $548.12. The firm has a market cap of $23.50 billion, a P/E ratio of 19.22, a P/E/G ratio of 1.93 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.19 EPS. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on UTHR. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Cantor Fitzgerald increased their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday. TD Cowen lifted their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $548.09.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.